Elranatamab Monotherapy

Phase II MRD-Adapted Study of Elranatamab in Relapsed/Refractory

More Information

Trial Status
Accepting patients
Trial Phase
Phase 2
Enrollment
33 patients (estimated)
Sponsors
University of California, San Diego
Tags
Bispecific T Cell Engager (BiTE), Bispecific Antibody, B-Cell Maturation Antigen (BCMA), CD3
Trial Type
Treatment
Last Update
SparkCures ID
2059
NCT Identifier
NCT06711705

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 850-0650

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.